DE4CC0DE-5FC3-4494-BCBF-4D50B00366B5

CVS Profit Misses Estimates As Retail Sales Growth Slows

By Publications Checkout
Share this article
CVS Profit Misses Estimates As Retail Sales Growth Slows

Retail pharmacy chain CVS Health Corp. missed analysts’ second-quarter earnings expectations as retail sales growth slowed.

Profit excluding one-time items was $1.19 a share, one cent below the average of analysts' estimates compiled by Bloomberg. Sales rose 7.4 per cent to $37.2 billion, the US-based company said in a statement. That was in line with analysts’ estimates.

The company also narrowed its full-year adjusted earnings forecast to $5.11-$5.18 a share from a previous forecast of $5.08-$5.19 a share. Analysts had projected $5.17 a share.

CVS, the largest provider of prescription drugs in the US, is expanding further beyond its retail roots with two second-quarter acquisitions. They are part of a record year for the health-care industry, with consolidation affecting insurers and drugmakers.

In May, CVS agreed to purchase nursing-home pharmacy Omnicare for $12.7 billion, expanding services to the country’s elderly. Less than four weeks later, CVS struck a deal to acquire Target's pharmacies and clinics for $1.9 billion, putting its brand, which includes OneMinute Clinics, in retail locations across 47 states.

ADVERTISEMENT

Pharmacy services' revenue rose 12 per cent in the second quarter to $24.4 billion, the company said.

Front-of-store sales for locations that have been open at least a year dropped 7.8 per cent, reflecting the company’s decision to stop selling tobacco products.

News by Bloomberg, edited by ESM. To subscribe to ESM: The European Supermarket Magazine, click here.

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.